BioVersys (BIOV)

Last close As at 30/12/2025

CHF24.40

−0.60 (−2.40%)

Market capitalisation

CHF0m

BioVersys is a multi-asset, clinical-stage biopharmaceutical company focussed on the development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant bacteria.

Latest Insights

Healthcare | Comment

BioVersys (SIX:BIOV) moves closer to Phase III with CTA filing

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Dr. Marc Gitzinger

    CEO & Founder

  • Hernan Levett

    CFO